How to buy Chimerix stock | $7.82

Chimerix, Inc is a biotechnology business based in the US. Chimerix shares (CMRX) are listed on the NASDAQ and all prices are listed in US Dollars. Chimerix employs 54 staff and has a trailing 12-month revenue of around 0.00.

Chimerix stock price (NASDAQ: CMRX)

Use our graph to track the performance of CMRX stocks over time.

Chimerix shares at a glance

• Key figures

Information last updated 2021-07-29.

Latest market close	$7.82
52-week range	$2.22 - $11.57
50-day moving average	$7.79
200-day moving average	$8.69
Wall St. target price	$17.83
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-1.32

Buy Chimerix shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Chimerix stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Chimerix, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Chimerix price performance over time

Historical closes compared with the close of $7.82 from 2021-05-28

1 week (2021-07-24)	N/A
1 month (2021-07-02)	-6.12%
3 months (2021-05-04)	-9.07%
6 months (2021-01-31)	N/A

1 year (2020-07-31)	N/A
2 years (2019-07-31)	N/A
3 years (2018-07-31)	N/A
5 years (2016-07-31)	N/A

Chimerix financials

Revenue TTM	$5.6 million
Gross profit TTM	$-30,860,000
Return on assets TTM	-22.6%
Return on equity TTM	-111.23%
Profit margin	0%
Book value	$1.55
Market capitalisation	$598.3 million

TTM: trailing 12 months

Shorting Chimerix shares

There are currently 3.2 million Chimerix shares held short by investors – that's known as Chimerix's "short interest". This figure is 5.9% down from 3.4 million last month.

There are a few different ways that this level of interest in shorting Chimerix shares can be evaluated.

Chimerix's "short interest ratio" (SIR)

Chimerix's "short interest ratio" (SIR) is the quantity of Chimerix shares currently shorted divided by the average quantity of Chimerix shares traded daily (recently around 719325.95936795). Chimerix's SIR currently stands at 4.43. In other words for every 100,000 Chimerix shares traded daily on the market, roughly 4430 shares are currently held short.

However Chimerix's short interest can also be evaluated against the total number of Chimerix shares, or, against the total number of tradable Chimerix shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Chimerix's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 Chimerix shares in existence, roughly 40 shares are currently held short) or 0.0479% of the tradable shares (for every 100,000 tradable Chimerix shares, roughly 48 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Chimerix.

Find out more about how you can short Chimerix stock.

Chimerix share dividends

We're not expecting Chimerix to pay a dividend over the next 12 months.

Chimerix share price volatility

Over the last 12 months, Chimerix's shares have ranged in value from as little as $2.22 up to $11.5696. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Chimerix's is 1.5696. This would suggest that Chimerix's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Chimerix overview

Chimerix, Inc. , a development-stage biopharmaceutical company, focuses on accelerating the advancement of various medicines that impact in the lives of patients living with cancer and other serious diseases. Its clinical stage development programs include brincidofovir (BCV), an antiviral drug candidate in development as a medical countermeasure for smallpox; dociparstat sodium (DSTAT), which inhibits the activities of key proteins implicated in the resistance of acute myeloid leukemia blasts and leukemic stem cells to chemotherapy; and ONC201 a program for potentially treating tumors which harbor the H3 K27M mutation in recurrent diffuse midline glioma patients. The company has license agreements with Biomedical Advanced Research and Development Authority for the development of brincidofovir for use in the treatment of smallpox; Cantex Pharmaceuticals, Inc. to develop and commercialize a glycosaminoglycan compound; and SymBio Pharmaceuticals to develop, manufacture, and commercialize BCV for various human indications. Chimerix, Inc. was incorporated in 2000 and is headquartered in Durham, North Carolina.

Frequently asked questions

What percentage of Chimerix is owned by insiders or institutions?
Currently 12.37% of Chimerix shares are held by insiders and 60.6% by institutions. How many people work for Chimerix?
Latest data suggests 54 work at Chimerix. When does the fiscal year end for Chimerix?
Chimerix's fiscal year ends in December. Where is Chimerix based?
Chimerix's address is: 2505 Meridian Parkway, Durham, NC, United States, 27713 What is Chimerix's ISIN number?
Chimerix's international securities identification number is: US16934W1062 What is Chimerix's CUSIP number?
Chimerix's Committee on Uniform Securities Identification Procedures number is: 16934W106